Dasatinib was developed to interact mainly with the ABL and SRC families of tyrosine kinases, thus blocking intracellular signaling transduction in Ph+ CML and ALL [28,29]. Here, SRC is linked to chronic myelogenous leukemia, BCR-ABL1 positive.